![]() | |
Clinical data | |
---|---|
Trade names | Agamree |
Other names | VBP; VBP-15; 17α,21-Dihydroxy-16α-methylpregna-1,4,9(11)-triene-3,20-dione |
AHFS/Drugs.com | Monograph |
MedlinePlus | a624005 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.032.874 |
Chemical and physical data | |
Formula | C22H28O4 |
Molar mass | 356.462 g·mol−1 |
3D model (JSmol) | |
| |
|
Vamorolone, sold under the brand name Agamree, is a synthetic corticosteroid, which is used for the treatment of Duchenne muscular dystrophy.[4][5][6][7][8] It is taken by mouth.[1] It is a dual atypical glucocorticoid and antimineralocorticoid.[9]
The most common adverse reactions include cushingoid features, psychiatric disorders, vomiting, increased weight, and vitamin D deficiency.[10]
Vamorolone was approved for medical use in the United States in October 2023,[11][10] and in the European Union in December 2023.[2][3]
Agamree EPAR
was invoked but never defined (see the help page).FDA approval
was invoked but never defined (see the help page).